# lumohs Standardizing safety in the most common procedures in medicine and aesthetics. - Canonical URL: https://wefunder.com/lumohs - Entity ID: wefunder:company:178027 - Last updated: 2026-06-06T14:50:44Z - Generated at: 2026-06-06T19:53:23Z ## Quick facts - Over 2,400 MVP units, handles & accessories, sold thru 5 distributors & direct to end user online. - Founder is a 30+ year clinician who built and uses lumohs for his own practice. - Notable personal investors from ex-Google/Wing VC and other notable venture investors. - Already raised $2M+ from Ex-CEO's Citrix, Digital Ocean, PPOM (Health ins.) & other notable execs. - Aesthetics-first entry with expansion into surgical & defense applications-$100B+ market opportunity - A “Harry’s Razor”–style model built with proprietary blade cartridges with recurring revenue & SAAS. - Capital-efficient: validated platform, scaled manufacturing, expanding device portfolio & reach. - lumohs controls manufacturing of hardware, consumables, & software platform with moat of 25+ patents ## Active fundraises - wefunder:fundraise:137971: 4(a)(6) successful (USD) - wefunder:fundraise:137970: 4(a)(6) open (USD) ## Story Lumohs was built to solve a problem clinicians have quietly accepted for decades. Clinicians and staff routinely handle exposed surgical blades.For more than 30 years, Dr. Steven Hacker has run a busy clinical practice where minor procedures were performed every day. Over that time, he repeatedly saw trained medical assistants and nurses injure themselves while handling razor-sharp blades.Cuts to the hands.Blood exposure.Trips to urgent care or the ER.Lost workdays and liability for clinics.These incidents were rarely treated as extraordinary. They were accepted as part of the job.At the same time, procedural visibility during many minor procedures remains limited. Lighting is often inconsistent, obstructed by hand shadowing, prohibitively expensive, or unavailable in many real-world environments.When procedures are performed millions of times each year, these risks add up quickly. Yet the core instrument used in these workflows, the handle, has barely evolved. Blade loading remains manual.We eliminate an entire line cost item. Savings huge. Safety Improved.Before Lumohs hospitals, clinics, doctor's offices to be compliant with OSHA and minimize risks of blade related injuries they need to buy, install and replace blade removers. This cost is completely gone as we built the blade loader and remover into the process. GONE. Saving all customers thousands on a safer better more efficient process.When injuries occur, the impact extends far beyond the individual incident. Hand lacerations and blood exposure translate into lost staff time, disrupted schedules, workers’ compensation claims, urgent care visits, and administrative overhead. Even minor injuries can remove trained personnel from the floor, slow patient throughput, and introduce operational friction into otherwise routine procedures.These injuries are not the result of complex medical decisions— they occur during interaction with exposed blades.Across high-volume practices these inefficiencies compound. Clinics lose productivity, incur avoidable costs, and accept slower patient turnover because the underlying tools were never designed with safety and visibility as integrated system requirements.The workflow problem hiding in plain sightHigh-volume procedures across aesthetics, dermatology, and minor surgery still rely on manual blade handling. Professionals are required to load and eject exposed blades by hand, creating an unavoidable occupational risk.At the same time, limited illumination and hand shadowing reduce visibility at the point of care, increasing the likelihood of imprecision during routine procedures.Despite the scale of these procedures, the tools used in these workflows have changed very little. The handle itself has become commoditized, and meaningful innovation has stalled.Redesigning the system, not the behaviorThe Lumohs team approaches the problem differently. Rather than improving a single component, Lumohs redesigns the workflow itself.First, blade handling risk is eliminated. Manual loading and ejection are replaced with a touchless cartridge system that removes direct contact with exposed blades.Second, provider visibility is enhanced. Illumination is integrated directly into the instrument, delivering consistent, on-axis light to the point of care.Not Cliche. We Really Are "A Razor: Razor Blade" Business.The result is a safer, faster, and more consistent workflow that fits seamlessly into existing clinical practice. Clinicians do not need to change how they work. They simply work with a better system.A platform built for durability and scaleLumohs is not a single device. It is a vertically integrated platform that combines proprietary hardware, patented consumables, and software-enabled workflows.Hardware enables adoption. Proprietary cartridges create repeat usage. Software supports training and procedural consistency. Together, these elements transform a historically commoditized instrument into a scalable platform with recurring usage.Past Prototypes. Commercially Shipping Today.Lumohs is designed not only as a procedural tool but as a connected platform.From Device to Connected PlatformFuture versions of the device integrate Bluetooth connectivity with a mobile application and cloud data infrastructure. During a dermaplaning session, the device can capture procedural telemetry such as blade angle, motion patterns, stroke cadence, session duration, and lighting settings.This vector information can be paired with AI facial images performed before and after treatments. Over time this creates a unique dataset linking dermaplaning technique with measurable skin results.This data can support practitioner feedback, training tools, and outcome-based skincare insights while helping standardize technique across industry.We call this intelligence layer Vector Intelligence. It's the AI engine that will predict skin outcomes from technique data and coach practitioners in real time — turning dermaplaning from an artisanal skill into a measurable, teachable technique. Vector Intelligence is in development today, launching on Gen 2 hardware and growing more valuable as our install base expands. Every procedure makes the model smarter. Every new clinic widens the lead.Example: GlowScoreLumohs is developing a simple performance metric called GlowScore.GlowScore converts dermaplaning session data and measured skin outcomes into an easy-to-understand score that reflects both technique quality and skin improvement.For practitioners, this provides feedback and training insights.For clients, it creates a measurable way to track skin improvement over time.GlowScore represents one example of how connected devices and outcome measurement can transform dermaplaning into a measurable procedure rather than an artisanal technique.Why aesthetics is the starting point: Hear directly from the founder, Dr. Steven Hacker alongside leading esthetician instructors (and watch Lumohs in action in the video below). Dermaplaning is now a standard component of professional facials across the United States. Approximately 150,000 licensed estheticians perform roughly 150,000 dermaplaning procedures each day, before accounting for all other surgical use. That represents an enormous number of blade-handling events occurring daily.The Lumohs team chose aesthetics as the entry market because it combines high procedure volume with rapid adoption of new professional tools. From this foundation, the same platform expands naturally into dermatology, surgery, emergency medicine, and defense applications.Initial Reviews of Gen 2 HandleImportantly, Lumohs was designed from the outset as a touchless blade-handling platform, not a single-use cosmetic tool. While Nano Surgical remains focused on professional aesthetics today, this design creates long-term enterprise optionality, including potential relevance in robotic and hybrid surgical settings, without changes to our current roadmap.Why NowSeveral industry shifts make this the right moment to modernize procedural tools. The aesthetics market has grown rapidly over the past decade, and dermaplaning is now a routine procedure performed hundreds of thousands of times each day.Clinics and medical practices are increasingly focused on occupational safety and work flow efficiency, particularly as staffing shortages make injuries and lost workdays more costly.At the same time, connected devices and measurable outcomes are becoming standard expectations across healthcare and professional beauty.Advances in electronics miniaturization, mobile software, and manufacturing now make it possible to integrate illumination, connectivity, and analytics directly into handheld instruments.Together these shifts create a clear opportunity to modernize a tool that has remained largely unchanged for decades.Revenue strategy and milestones.The Lumohs platform has already demonstrated real-world demand with real-world execution.Over 2,400 units — handles, batteries, and accessories — have been sold through five wholesale distributors and direct-to-practitioner retail, with little to zero marketing spend. Second-generation platform is launching May 2026 with pre-order demand from existing customers. Manufacturing, regulatory pathways, and operational infrastructure are now established.Nano Surgical is no longer searching for product-market fit. The focus is now on scaling production, expanding distribution, and increasing recurring consumable usage.In 2025, we made a deliberate choice. After proving product-market fit with our first-generation device, we redirected every resource into building the second-generation platform — launching May 2026 and funded by this round. The revenue dip and net loss are the shape of that decision: R&D, tooling, IP, and regulatory work instead of chasing more MVP sales. We chose to build the next product rather than squeeze the last one.Real products. Real brand. Really Online.The next phase of growth builds on the existing platform.A key milestone is the upcoming Single-Use Lumohs Sterile Handle, designed for environments where reusable tools are impractical or not permitted. These environments include clinics, emergency response, military medicine, and field medical settings where disposable workflows are required and lighting is often limited.Single-use Platform- Designed for military applications, surgical kits for trauma & emergency care (night vision needed). Lumohs can serve these environments while maintaining the same touchless blade-handling system and integrated illumination.Defensibility rooted in design and executionNano Surgical has built a defensible ecosystem around the Lumohs platform. The company holds more than 25+ patents (12+ issued, 12 pending) , primarily utility patents, covering blade loading mechanisms, illumination systems and cartridge architecture. By controlling both the hardware and the proprietary consumables that enable the system, Nano Surgical creates a durable competitive advantage that is difficult to replicate.Beyond hardware and consumables, Nano Surgical is building a data moat. Technique telemetry paired with before-and-after skin scans creates a proprietary dataset no competitor can replicate without owning the hardware layer — and Vector Intelligence turns that dataset into a compounding advantage that strengthens with every procedure performed on the platform.Made in USAVertically integrated from day one.Nano Surgical owns the molds, the tooling, and all device designs outright. This gives Nano Surgical full control over production quality, cost structure and the ability to iterate rapidly without dependency on third party IP.Our FDA compliant U.S. manufacturing partner produces every device domestically - supporting regulatory alignment and quality standards.Founder-market fit at the centerLumohs exists because its founder experienced the problem firsthand.Dr. Steven Hacker is a dermatologist with more than 30 years of clinical experience who built the product he wanted to use in his own practice. That clinical perspective informs the design, safety priorities, and practical realities of adoption.Why the Lumohs team chose WefunderWefunder allows Nano Surgical to align its customer with its long-term mission. Practitioners understand this problem directly because they experience it every day. By giving clinicians and users the opportunity to become shareholders, the company builds a community that is financially and operationally invested in the platform's success.Use of capitalCapital from this round will be used to:expand manufacturing inventory tooling,increase production capacity,scale distribution and go-to-market execution,continue development of the Lumohs platform.Looking aheadNano Surgical is building a future where procedural safety, visibility, and intelligence are designed directly into the tools clinicians use every day. Touchless blade handling, integrated illumination, and Vector Intelligence turn millions of routine procedures into a compounding data advantage.By combining touchless blade handling with integrated illumination, Lumohs improves safety and visibility across millions of procedures performed each year.The company is now scaling manufacturing, expanding distribution and growing the Lumohs Platform.Invest in Nano Surgical and help modernize procedural safety. ## FAQ 1. **amazing! I invested in a bunch of clinics rather recently, therefore, this caught my eye. few questions. 1. what is your max capacity now? what are you aiming for? 2. I noticed on your website you don't have a referral, affiliate or ambassador program. do you plan on adding th...** - John, thank you for the thoughtful questions — I appreciate the interest. 1. Capacity & Scaling We have planned manufacturing capacity in place to scale with demand. To date, we have intentionally not fully optimized production (for example, running multiple shifts) because demand has not yet required it. However, the tooling, molds, and production processes were developed from the outset with scale in mind, so we can increase output quickly when needed rather than rebuilding infrastructu... 2. **Sounds Amazing. How many patents/ including pending does the company have? (And do I - a regular guy - have a particular use for the Lumos Pro Kit for myself?) Thanks in advance,** - Great questions — appreciate you asking. Patents / IP: Nano Surgical has built a strong and expanding IP portfolio around the Lumohs platform, with 30+ patents spanning issued and pending filings. This includes 13 granted and issued utility patents, ~4 granted design patents, along with multiple pending applications and international PCT filings covering core device design, illumination, safety, and workflow innovations. Personal use question (non-professional): The Lumohs Pro Kit is primaril... 3. **final questions you did a great job explaining everything and I see info on your website. probably should have looked at that first before I asked about affiliate program. you mentioned this as as a response to one of my questions. 1. "To date, we have intentionally not fully ...** - Thank you for the thoughtful questions, I really appreciate them.Demand & Marketing: Demand is building and we are currently in a controlled launch phase rather than full mass distribution. We focused first on manufacturing, sterilization, packaging, and fulfillment so we can scale properly. We have a meaningful number of paid pre-orders in the queue and expect to begin shipping around mid-May. Our growth strategy includes direct sales to medspas and estheticians, medical and aesthetic di... 4. **Been in the medical business 40 plus years and the surgeon replacing his own blades went out of style before polio vaccine was developed. Most if not all surgeons use disposable scaples with blades ATTACHED already. No sale for me.** - Jeff, thank you for the comment and for your many years in the medical field. You are absolutely correct that in many operating rooms disposable scalpels with pre-attached blades are commonly used today.However, what many people don’t realize is that there are still over 15,000 dermatologists in the U.S., along with tens of thousands of plastic surgeons, Mohs surgeons, podiatrists, veterinarians, military medicine, clinics, and international settings that still use reusable handles with steri... 5. **Sounds Promising. I have couple of questions. 1. The Form C shows $184,347 in accounts receivable against $333 in recognized revenue. What accounts for this discrepancy 2. How many Lumohs Pro units have been sold or placed to date, and what is the average selling price per uni...** - Quick responses to each question below: Question 1: The Form C shows $184,347 in accounts receivable against $333 in recognized revenue. What accounts for this discrepancy?I think there may be a misread on the balance sheet. The $184,347 figure is total assets at end of 2024, not accounts receivable. Our AR was $0 in 2024 and $333 in 2025. The $333 you referenced is the 2025 AR balance, not revenue.Revenue was $129,949 in 2024 and $43,676 in 2025. The decline was intentional. 2025 was a trans... ## Team - Steven Hacker (President & CEO) - Zack Monninger (VP, Product Development) - Amina Venton (Program & IT Lead) - Craig Rettew (Electrical Engineer) - Stephanie Hess (Operations & Regulatory) ## Recent posts - Physician Safety. Patient Safety. Closed-Loop Ingenuity. (2026-05-31T21:59:18Z) - We just gave estheticians something they've never had: proof. (2026-05-28T19:37:39Z) - A vertical worth sharing: emergency medical kits (2026-05-17T21:50:09Z) - A milestone worth sharing with our investor community. (2026-05-11T18:44:49Z) - Common misconception: our cartridge system creates plastic waste. Reality: it eliminates it. 300M individually wrapped blades hit landfill yearly. 500M disposable handles. Zero recycled. Lumohs loaders reuses recycled plastic, ships back, and regrounds to resin. Safer for practitioner. Safer for patient. Watch the math. (2026-05-10T10:17:49Z) - When the Lights Go Out, Lumohs Goes On: 60 Seconds to a Surgical Airway (2026-05-08T17:27:50Z) - How we save practitioners $240 per room per year. (2026-05-02T13:33:30Z) - BEFORE Lumohs: Estheticians, surgeons & hospitals spending $240/year per room on blade removers. Per. Room. Plus the constant risk of blade injuries. AFTER Lumohs: Built-in Blade Eject. Safer. Blade injury risk — eliminated. Save $240 per room AND remove the injury risk at the same time. Multiple rooms? That's a vacation. (2026-05-02T13:26:29Z) - What It Takes to Build a Better Handle in America (2026-04-26T14:49:45Z) - Harder Than Expected: Inside US Manufacturing 🤫 Sneak peek alert — An early look at the Lumohs Eclipse, prior to public launch. What we underestimated wasn't the design — it was the testing. Every part is machined, assembled, and validated in our US facility. Tolerance, durability, function. No exceptions. No shortcuts. (2026-04-26T13:40:56Z) - Hardware + AI + App: Building the OS for the $20B Med Spa Boom (2026-04-19T12:39:35Z) - Shipping day 📦 This is what 150 orders looks like behind the scenes. We're personally packing our first batch of Lumohs Pro before fulfillment moves to our 3PL — because we wanted every single one of these to pass through our hands first. Carefully packed, & headed out to the practitioners who believed in us early. (2026-04-18T21:08:41Z) - (2026-04-15T15:25:14Z) - No hands. Ever. (2026-04-13T18:32:56Z) - Years of work looks like this. (2026-04-08T11:56:46Z) ## Q&A - Q: Hi Steven, I’m currently reviewing the Lumohs opportunity. The product looks very interesting, and I had a few questions around commercialization and scaling that would help me better understand the business. -You mentioned approximately 130 Lumohs Pro units have been sold so far. Approximately how many unique clinics, practices, or professionals does this represent, and what percentage of customers are actively reordering blades, consumables, or accessories? -Revenue declined during the transition from Gen 1 to Gen 2, which makes sense strategically. What evidence are you seeing today that gives you confidence Gen 2 revenue can exceed prior Gen 1 revenue levels, and when do you expect revenue growth to reaccelerate? -Without disclosing sensitive unit economics, which part of the business do you expect to become the primary long-term profit driver: hardware sales, consumables, subscriptions, software/data products, or something else? -What specific milestone would management consider a successful outcome for this raise? For example: installed devices, revenue targets, active customers, distribution expansion, profitability, etc. Based on current plans, do you expect another funding round before reaching those milestones, or do you believe this raise provides sufficient capital to get there? I appreciate all the answers so far! - A: Jonathon-thanks for the thoughtful questions.1. Unique clinics/professionals, and reorder rate.The ~135 Pro units are a mix of discounted Gen 1 upgrades and new buyers at full retail. We're working on the basis that each handle shipped to an individual address represents one individual account, so that number tracks closely to the number of distinct practices and professionals using the device. On reorders, our broader marketing push is only now starting, so these units are just entering their first consumable cycles. Blade reorder rate is the metric that matters most here, and it's the one we'll report as the base matures. I'd rather give you a real number later than an early small percentage now. What i will say, is we are seeing re-order rates already of just our cartridge refills. Our strategy includes adding leading blade manufacturers to our system and as this grows, so does customer appeal (as often blade usage is tied to brand preference) . 2. Confidence Gen 2 beats Gen 1, and timing.The 2025 dip was deliberate. We stopped selling our single Gen 1 device and spent the year building the platform, tooling, inventory, and regulatory work behind it. That's investment, not decline. Three reasons I'm confident: we've sold ~135 units with almost no marketing, just email to our existing base; the model now pulls recurring blade revenue behind every placement, a tail Gen 1 never had; and we have real distribution momentum, led by McKesson and which produced many real leads at their national sales conference, plus more distributor deals in progress and our first major trade show on June 25. Our marketing push begins this summer, so the back half of 2026 is where we look to see reorders start compounding.3. Primary long-term profit driver.Recurring revenue, not hardware. The handle is the razor and our proprietary blade cartridges are the blades, designed to work only with our handles. Hardware builds the installed base; consumables are the engine and carry the repeatable margins. Longer term, software and data layered on that base through our Lumoglo app become the compounding layer on top.4. Success milestone for this raise, and future funding.Success is proving the platform's recurring-revenue flywheel works at scale: a growing installed base, a healthy blade reorder rate on it, and distribution expansion, meaning relationships like McKesson turning into recurring purchase orders. The capital funds manufacturing scale-up, inventory, additional regulatory, and converting our pipeline into live accounts along with reaching out to new customers . On future funding, this raise is sized to fund the current scale-up phase, and we'd expect a future round to push into the larger global and rapid expansion once these milestones are proven.Appreciate the questions. Glad to go deeper on any of these. - A: Jonathon-thanks for the thoughtful questions.1. Unique clinics/professionals, and reorder rate.The ~135 Pro units are a mix of discounted Gen 1 upgrades and new buyers at full retail. We're working on the basis that each handle shipped to an individual address represents one individual account, so that number tracks closely to the number of distinct practices and professionals using the device. On reorders, our broader marketing push is only now starting, so these units are just entering their first consumable cycles. Blade reorder rate is the metric that matters most here, and it's the one we'll report as the base matures. I'd rather give you a real number later than an early small percentage now. What i will say, is we are seeing re-order rates already of just our cartridge refills. Our strategy includes adding leading blade manufacturers to our system and as this grows, so does customer appeal (as often blade usage is tied to brand preference) . 2. Confidence Gen 2 beats Gen 1, and timing.The 2025 dip was deliberate. We stopped selling our single Gen 1 device and spent the year building the platform, tooling, inventory, and regulatory work behind it. That's investment, not decline. Three reasons I'm confident: we've sold ~135 units with almost no marketing, just email to our existing base; the model now pulls recurring blade revenue behind every placement, a tail Gen 1 never had; and we have real distribution momentum, led by McKesson and which produced many real leads at their national sales conference, plus more distributor deals in progress and our first major trade show on June 25. Our marketing push begins this summer, so the back half of 2026 is where we look to see reorders start compounding.3. Primary long-term profit driver.Recurring revenue, not hardware. The handle is the razor and our proprietary blade cartridges are the blades, designed to work only with our handles. Hardware builds the installed base; consumables are the engine and carry the repeatable margins. Longer term, software and data layered on that base through our Lumoglo app become the compounding layer on top.4. Success milestone for this raise, and future funding.Success is proving the platform's recurring-revenue flywheel works at scale: a growing installed base, a healthy blade reorder rate on it, and distribution expansion, meaning relationships like McKesson turning into recurring purchase orders. The capital funds manufacturing scale-up, inventory, additional regulatory, and converting our pipeline into live accounts along with reaching out to new customers . On future funding, this raise is sized to fund the current scale-up phase, and we'd expect a future round to push into the larger global and rapid expansion once these milestones are proven.Appreciate the questions. Glad to go deeper on any of these. - Q: Sounds Promising. I have couple of questions. 1. The Form C shows $184,347 in accounts receivable against $333 in recognized revenue. What accounts for this discrepancy 2. How many Lumohs Pro units have been sold or placed to date, and what is the average selling price per unit? How many practices are currently active blade reorder customers? 3. What is your blade consumable margin — what does it cost to manufacture a blade cartridge vs. what you charge practitioners? 4. Have any large distributors (Henry Schein, Patterson Companies, or aesthetics-focused distributors) evaluated the product? What was their feedback or barrier to a distribution agreement? - A: Quick responses to each question below: Question 1: The Form C shows $184,347 in accounts receivable against $333 in recognized revenue. What accounts for this discrepancy?I think there may be a misread on the balance sheet. The $184,347 figure is total assets at end of 2024, not accounts receivable. Our AR was $0 in 2024 and $333 in 2025. The $333 you referenced is the 2025 AR balance, not revenue.Revenue was $129,949 in 2024 and $43,676 in 2025. The decline was intentional. 2025 was a transition year where we moved beyond our single Gen 1 device and built out a platform of devices with recurring blade consumables, shifting from one-time hardware sales to an installed base with ongoing cartridge revenue.That investment shows up on the asset side, with total assets growing more than 8x year over year. We invested in manufacturing molds and tooling designed to scale across the platform, including future devices produced through interchangeable inserts without new molds. We also vertically integrated, so we own the molds, manufacturing, and IP. Happy to walk through any line item in more detail.Question 2: How many Lumohs Pro units have been sold, ASP, and active blade reorder customers?We're at the very beginning of our commercial launch for Lumohs Pro, the first device on our platform.To date we have 130 units sold, including discounted upgrades from Gen 1 customers and new buyers at full retail. We have not yet started active marketing beyond email to our Gen 1 base, and are targeting July 1 for our broader push.On reorders, our strategy is to offer a range of blade types compatible with our loaders and proprietary cartridges, so we cover what most practitioners already prefer to use. Blade reorder rate will be a primary metric we track as the launch matures.We're holding off on exact ASP while we finalize pricing tiers.Question 3: What is your blade consumable margin?Our blade cartridges carry healthy margins consistent with single-use medical accessory norms. We're not disclosing exact unit economics publicly at this stage, since it affects our negotiating position with distributors and large practice accounts.Question 4: Have any large distributors evaluated the product?McKesson is our most significant large distributor development. After a lengthy evaluation period they added Nano Surgical as a new supplier, and last week we participated in their annual National Sales Conference. Our booth was very busy with their reps, and we came away with over 70 leads to follow up on. McKesson is the first major distributor to bring us into their catalog after full evaluation, and they're preparing to roll out to their rep network.Henry Schein added our single Gen 1 handle to their catalog in 2024 but we chose not to invest in that relationship once we committed to moving away from Gen 1 to the current platform. We plan to re-engage Henry Schein and other prior Gen 1 partners, including smaller boutique distributors and larger players like Scien, now that the platform is ready.We've also started relationships with Service Disabled Veteran-owned medical distributors to address the VA hospital and government sales channel. All others are on the roadmap post-launch. - Q: Been in the medical business 40 plus years and the surgeon replacing his own blades went out of style before polio vaccine was developed. Most if not all surgeons use disposable scaples with blades ATTACHED already. No sale for me. - A: Jeff, thank you for the comment and for your many years in the medical field. You are absolutely correct that in many operating rooms disposable scalpels with pre-attached blades are commonly used today.However, what many people don’t realize is that there are still over 15,000 dermatologists in the U.S., along with tens of thousands of plastic surgeons, Mohs surgeons, podiatrists, veterinarians, military medicine, clinics, and international settings that still use reusable handles with sterile blades that are loaded and removed between cases. Millions of procedures annually are still performed this way. This is especially true in specialties that use autoclaves.Because of that, there are actually two large markets:1. Disposable scalpels with attached blades2. Reusable handles with replaceable sterile bladesOur technology applies to both markets. We make a touchless blade loading system for reusable handles, and we also make single-use disposable illuminated scalpels for customers who prefer disposable instruments.So this isn’t a bet on only one workflow. It’s a platform that improves safety and visibility across multiple blade systems and multiple specialties.We very much appreciate the perspective and the discussion. - Q: Sounds Amazing. How many patents/ including pending does the company have? (And do I - a regular guy - have a particular use for the Lumos Pro Kit for myself?) Thanks in advance, - A: Great questions — appreciate you asking. Patents / IP: Nano Surgical has built a strong and expanding IP portfolio around the Lumohs platform, with 30+ patents spanning issued and pending filings. This includes 13 granted and issued utility patents, ~4 granted design patents, along with multiple pending applications and international PCT filings covering core device design, illumination, safety, and workflow innovations. Personal use question (non-professional): The Lumohs Pro Kit is primarily designed for professionals — estheticians, dermatologists, and procedural users — where lighting, precision, and safety meaningfully impact outcomes. For a typical consumer: It’s not necessary for everyday skincare It’s more advanced than what most individuals need Its value is highest in clinical or high-frequency treatment settings - Q: amazing! I invested in a bunch of clinics rather recently, therefore, this caught my eye. few questions. 1. what is your max capacity now? what are you aiming for? 2. I noticed on your website you don't have a referral, affiliate or ambassador program. do you plan on adding that one day? ambassador would be huge for you! 3. do you have any loi's, soft orders etc? 4. how is your revenue looking now. are you profitable etc? thanks for your time! - A: John, thank you for the thoughtful questions — I appreciate the interest. 1. Capacity & Scaling We have planned manufacturing capacity in place to scale with demand. To date, we have intentionally not fully optimized production (for example, running multiple shifts) because demand has not yet required it. However, the tooling, molds, and production processes were developed from the outset with scale in mind, so we can increase output quickly when needed rather than rebuilding infrastructure later. 2. Referral / Affiliate / Ambassador Programs Yes — we already have several hundred affiliates that actively requested approval to be affiliates with us and signed up (not passive enrollment) . We have not actively cultivated the program yet because we were transitioning from our first-generation device and did not want broad promotion of Gen 1 while Gen 2 was in development. As we move into the Gen 2 launch, activating and expanding ambassador and referral efforts becomes a much larger priority. 3. LOIs / Soft Orders / Demand Signals Rather than traditional LOIs, we track demand through paid upgrades and pre-orders. We recently offered existing users a paid Gen 2 upgrade path (shipping fee only). Among the customers who opened those emails, approximately 80% converted to an upgrade purchase, which we view as a strong indicator of product loyalty and forward demand. We are also seeing new customer pre-orders for Gen 2. 4. Revenue / Profitability We are currently in a growth and reinvestment phase rather than optimizing for net profitability. That said, our gross profit margins range approximately 50–80% depending on product category, which supports a strong long-term hardware-plus-consumable model as scale increases. - Q: final questions you did a great job explaining everything and I see info on your website. probably should have looked at that first before I asked about affiliate program. you mentioned this as as a response to one of my questions. 1. "To date, we have intentionally not fully optimized production (for example, running multiple shifts) because demand has not yet required it." how does demand look now and how are you marketing it(outside of affiliate programs) cause every clinic, surgery center etc can use this and it is very affordable. this product should be selling like hot cakes, demand should be there fast. I was confused about that. I have seen other with amazing products not have demand cause they didn't know how to fully market it. 2. some companies give projections and say no guarantees but this is what we are shooting for. then other companies say we can't give that cause of x,y and z. which makes no sense cause no companies would be giving roi projections on this page. do you have any roi etc. what you are hoping for financially for company and investors you aren't saying anything. 3. is your goal to do an IPO, get acquired etc. what is exit strategy? thanks for your time! - A: Thank you for the thoughtful questions, I really appreciate them.Demand & Marketing: Demand is building and we are currently in a controlled launch phase rather than full mass distribution. We focused first on manufacturing, sterilization, packaging, and fulfillment so we can scale properly. We have a meaningful number of paid pre-orders in the queue and expect to begin shipping around mid-May. Our growth strategy includes direct sales to medspas and estheticians, medical and aesthetic distributors, conferences and training programs, Amazon and Shopify, key opinion leaders, and a recurring blade cartridge subscription model.Financials / ROI: Because this is a Regulation CF offering, we cannot provide specific ROI projections, but the business model is a classic razor/razor blade model: sell the device platform and generate recurring revenue from blades and disposables, with software and data added over time. Our focus is building a large, recurring revenue platform company.Exit Strategy: The long-term goal would likely be acquisition by a medical device, surgical supply, or aesthetic device company, or potentially an IPO if the company grows large enough. Most companies in this space ultimately exit through strategic acquisition.Thanks again for the great questions and for taking the time to understand what we’re building.